Vascular dysfunction: a Janus face of visfatin in diabetes?

Metabolism: Clinical and Experimental

Volumn 56, Issue 4, 2007, Pages 459-461

  Teoh, Hwee ^a   Lovren, Fina ^a   Verma, Subodh ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; VISFATIN;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; BODY WEIGHT; CELL FUNCTION; CORRELATION ANALYSIS; DNA LIBRARY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANDEMIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASCULAR DISEASE;

COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 33947212509     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.12.002     Document Type: Article

References (16)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Giorgino F., Laviola L., and Eriksson J.W. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 183 (2005) 13-30
3. Lau D.C., Dhillon B., Yan H., Szmitko P.E., and Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288 (2005) H2031-H2041
4. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
5. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431-1437
6. Hammarstedt A., Pihlajamaki J., Rotter Sopasakis V., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab (2006) 1181-1184
7. Kralisch S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185 (2005) R1-R8
8. Hug C., and Lodish H.F. Medicine. Visfatin: a new adipokine. Science (2005) 366-367
9. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes. Metabolism 56 (2007) 451-458
10. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
11. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract (2006)
12. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., and Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49 (2006) 1909-1914
13. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
14. Ando H., Yanagihara H., Hayashi Y., Obi Y., Tsuruoka S., Takamura T., et al. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue. Endocrinology 146 (2005) 5631-5636
15. Hartge MM, Kintscher U, Unger T. Endothelial dysfunction and its role in diabetic vascular disease. Endocrinol Metab Clin North Am 2006:35:551-60, viii-ix.
16. Vigili de Kreutzenberg S., Kiwanuka E., Tiengo A., and Avogaro A. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 24 (2003) 1210-1215